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Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces
strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we
used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization.
The present study explores whether HIV-DNA priming can be simplified by reducing the
number of DNA injections and administration of combined versus separated plasmid pools.
Methods
In this phase IIa, randomized trial, priming was performed using 5 injections of HIV-DNA,
1000 μg total dose, (3 Env and 2 Gag encoding plasmids) compared to two “simplified”
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regimens of 2 injections of HIV-DNA, 600 μg total dose, of Env- and Gag-encoding plasmid
pools with each pool either administered separately or combined. HIV-DNA immunizations
were given intradermally at weeks 0, 4, and 12. Boosting was performed intramuscularly
with 108 pfu HIV-MVA at weeks 30 and 46.
Results
129 healthy Tanzanian participants were enrolled. There were no differences in adverse
events between the groups. The proportion of IFN-γ ELISpot responders to Gag and/or Env
peptides after the second HIV-MVA boost did not differ significantly between the groups
primed with 2 injections of combined HIV-DNA pools, 2 injections with separated pools, and
5 injections with separated pools (90%, 97% and 97%). There were no significant differ-
ences in the magnitude of Gag and/or Env IFN-γ ELISpot responses, in CD4+ and CD8+ T
cell responses measured as IFN-γ/IL-2 production by intracellular cytokine staining (ICS) or
in response rates and median titers for binding antibodies to Env gp160 between
study groups.
Conclusions
A simplified intradermal vaccination regimen with 2 injections of a total of 600 μg with com-
bined HIV-DNA plasmids primed cellular responses as efficiently as the standard regimen
of 5 injections of a total of 1000 μg with separated plasmid pools after boosting twice with
HIV-MVA.
Trial Registration
World Health Organization International Clinical Trials Registry Platform
PACTR2010050002122368
Introduction
The global HIV pandemic is not yet under control despite reported recent decline in incidence
[1]. According to the UNAIDS report for the year 2014 there were a total of 35.3 million people
living with HIV, 2.1 million new infections, with 69% of all people living with HIV from sub-
Saharan Africa and 1.5 million deaths attributed to HIV [2]. The currently available HIV pre-
ventive and control interventions require strict adherence to be effective [3,4,5] with a threat of
recidivism [6,7]. Therefore there is still a need to prevent and control the large number of new
infections by complementing on-going interventions such as early detection, education on be-
havioral change and biomedical strategies with a safe, affordable and effective preventative
HIV vaccine.
The search for an HIV vaccine during the past 25 years has been a challenge due to viral di-
versity and the ability of the persistently virus—infected cells to evade the immune system [8].
However pre-clinical studies have identified immune and genetic biomarkers associated with
protection against challenge that provide further insights for an HIV preventive vaccine for hu-
mans [9,10,11,12,13].
So far there have been more than 180 clinical HIV-1 vaccine trials conducted in humans
ranging from phase I to phase III [14], including the recently concluded RV 144 phase III trial
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in Thailand that showed a modest efficacy of 31% [15]. Post-hoc analysis of the RV144 trial
evaluating associations between immune responses to vaccine and protection suggests that
binding IgG antibodies specific to the variable regions 1 and 2 of the HIV-1 envelope protein
are important [16,17,18]. An effective vaccine would be one that is capable of eliciting both an-
tibodies and T cells that have antiviral capabilities [19].
Tanzania is one of the sub-Saharan countries that has been highly affected by HIV, and has
participated in early phase I/II HIV vaccine trials [20]. Earlier studies evaluated different routes
for HIV-DNA vaccine administration comparing intradermal to intramuscular routes of
HIV-DNA delivery [20,21]. We have shown that intradermal priming thrice with 1000 μg of
an HIV-DNA vaccine per immunization given as 5 injections of 0.1 ml and separating Env and
Gag plasmid pools prior to boosting twice with an HIV-MVA vaccinia vector vaccine was safe
and resulted in strong and broad antigen-specific cellular immune responses to HIV Gag and
Env [20,22]. Importantly this study also showed that all vaccinees developed binding anti-HIV
antibodies, and a high proportion had antibodies reactive in a peripheral mononuclear cell
(PBMC) neutralization assay after the second HIV-MVA boost[20,22].
With overall feasibility in mind, it would be ideal to reduce the number of injections and
combine the plasmid pools into a single injection. We therefore set out to address two ques-
tions. Firstly, could the number of injections be reduced to 2 per immunization, and secondly
could the regimen be further simplified by combining the plasmid pools. Due to constraints in
the volume that could be delivered intradermally and the highest available DNA concentration
we compared the safety and immunogenicity of administering five injections of HIV-DNA at a
total dose of 1000 μg (5x0.1mL of 2mg/mL) of separated plasmids (“standard regimen”), with a
“simplified regimen” comprising 2 injections of a lower overall dose of 600 μg (2x0.1mL of
3mg/mL). We also compared the effect of combining versus separating the plasmid pools for
the overall safety and immunogenicity.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the institutional review boards of the Muhimbili University
of Health and Allied Sciences, and the Mbeya Medical Research Ethics Committee. The Tanza-
nia National Institute for Medical Research (NIMR), serving as the National Ethics Committee,
and the Swedish Ethics Committee also approved the study. The Tanzania Food and Drugs Au-
thority (TFDA) approved the candidate HIV-DNA and HIV-MVA vaccines for use in humans
in Tanzania. This study was conducted according to the principles of International Communi-
ty of Harmonization and Good Clinical Practice guidelines (ICH-GCP). All participants had at
least primary level education and non had a compromised ability to consent. All participants
were provided with an information sheet to read and were recruited after having signed the
study informed consent.
Study Design and Population
This was a phase IIa randomized clinical trial that recruited participants from two centers in
Tanzania: the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam,
and the National Institute for Medical Research (NIMR)-Mbeya Medical Research Center
(NIMR-MMRC) in Mbeya. The study protocol and CONSORT checklist are available as sup-
porting information; see Checklist A and Protocol A in S1 File. The trial is registered at the
World Health Organization International Clinical Trials Registry Platform, on the 31st of May
2010 with registration number PACTR2010050002122368 that is available at http://apps.who.
int/trialsearch/trial.aspx?trialid=PACTR2010050002122368. The data are filed at the study
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sponsor and will be made available upon written request to the study Sponsor, the Public
Health Agency of Sweden, at registrator@folkhalsomyndigheten.se.
The trial participants were recruited among officers in Police and Prison forces, as well as
youths from a Youth friendly clinic in Dar es Salaam. In Mbeya participants were recruited
from the general population.
The study protocol aimed to include 120 healthy individuals (60 from each center), aged
18–40 years who were regarded to be at low risk for acquiring HIV infection, and were willing
to undergo HIV and pregnancy testing (for females) at screening and during the trial duration
of 70 weeks. Participants were also required to use an effective method of contraception
throughout the trial.
Replacements were performed for early dropouts or withdrawals from immunization during
ongoing recruitment. All participants received detailed study information prior to screening
and enrollment during pre-screening and briefing workshops. All participants were required to
sign an informed consent form before enrollment. The participants were also required to have
undergone and passed a test of understanding about the study prior to enrollment.
Volunteers were excluded if they were HIV-infected, pregnant, had any clinically relevant
medical condition or abnormal laboratory findings that included Hepatitis B virus infection,
syphilis, diabetes, were known to be using immunosuppressive medications or had baseline
ECG findings indicating cardiac disease or likely to complicate later interpretation of peri/myo-
carditis. Recruitment began on the 10th of June 2010 and the final follow up visit was in June
2012. The study protocol received approval from the local ethics and National ethics commit-
tee the 9th of November 2009 and the 31st of December 2009 respectively
Randomization and Vaccinations
The trial participants were randomized to one of the three main study groups as summarized
in Table 1 and Fig 1: “2 injections combined”, “2 injections separated” and “standard”5 injec-
tions separated”. Within each main group participants were block randomized to vaccine or
Table 1. Randomized study groups, doses and routes of HIV-DNA and HIV-MVA vaccinations.
Group Number of
participants
HIV-DNA/Placebo weeks 0,4 and12 HIV-MVA/Placebo
weeks 30 and 46
Left arm Right arm Left arm
IA 36 1 injection ID of 0.1ml (3mg/ml). Pool 1
(EnvABC/RevB) and Pool 2 (GagAB/RTmutB).
Total dose 300 μg DNA. Pool 1& Pool 2
combined
1 injection ID of 0.1ml (3mg/ml). Pool 1(EnvABC/
RevB) and Pool 2 (GagAB/RTmutB). Total dose
300 μg DNA. Pool 1 and Pool 2 combined
1 injection IM of
MVA-CMDR A_E. 1 ml
108 pfu.
IB 4 1injection ID of 0.1ml saline 1injection ID of 0.1ml saline 1 injection IM of 1ml
saline
IIA 36 1 injection ID of 0.1ml (3mg/ml). Pool 1
(EnvABC/RevB) separated. Total dose 300 μg
DNA
1 injection ID of 0.1ml (3mg/ml). Pool 2 (GagAB/
RTmutB) separated. Total dose 300 μg DNA
1 injection IM of
MVA-CMDR A_E. 1 ml
108 pfu.
IIB 4 1injection ID of 0.1ml saline 1injection ID of 0.1ml saline 1 injection IM of 1ml
saline.
IIIA 36 3 injections ID of 0.1ml (2mg/ml). Pool 1
(EnvABC/RevB) separated. Total dose 600 μg
DNA
2 injections ID of 0.1ml (2mg/ml) Pool 2 (GagAB/
RTmutB) separated. Total dose 400 μg DNA
1 injection I.M,
MVA-CMDR A_E. 1 ml
108 pfu.
IIIB 4 3 injections ID of 0.1 ml saline 2 injections ID of 0.1 saline 1 injection I.M, 1ml
saline.
Note: ID = intradermal, IM = intramuscular, pfu = plaque forming units.
Combined refers to a combination of plasmid pools 1 and 2, separated refers to each plasmid pool given separately.
doi:10.1371/journal.pone.0119629.t001
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placebo in a ratio of 9:1. Blocks of 10 individuals consisting of 3 in group I, 3 in group II, 3 in
group III vaccine and one placebo allocation were randomized by the sponsor using random
numbers generated from http://www.random.org/list/. Six blocks were assigned to each site in
the form of a list maintained by the study pharmacist at each site. On the request of the clinic
the pharmacist allocated the enrolled volunteer to a consecutive slot on the list. The clinic was
not informed of vaccine/placebo allocation. Saline was used as a placebo to minimize the risk
that participants would mistakenly believe themselves to be protected against HIV. The place-
bo was also used to blind staff and participants when reporting adverse events. The three sets
of intradermal (ID) injections of HIV-DNA/Placebo were administered at weeks 0, 4 and 12.
The two intramuscular (IM) boosting vaccinations with HIV-MVA/Placebo were given at
weeks 30 and 46. The HIV-DNA/Placebo was administered in doses of 0.1 ml intradermally in
the skin over the deltoid muscle using a Biojector needle-less device (Bioject Medical Technolo-
gies, Inc., Tualatin, OR, USA). The HIV- MVA/Placebo vaccinations were administered with a
needle and syringe in a volume of 1 ml in the left deltoid muscle.
Vaccines
The HIV-1 DNA (HIVIS DNA) vaccine was manufactured by Vecura, (Huddinge, Stockholm,
Sweden). The HIV-DNA vaccine was composed of 7 plasmids carrying different HIV-1 genes.
Pool 1 comprised plasmids encoding Env subtypes A, B and C and Rev subtype B while pool 2
comprised plasmids encoding Gag subtypes A, B and RTmut subtype B. A more detailed de-
scription of the HIV-DNA vaccine is given by Brave et al [23,24].
The HIV-DNA concentration was 3 mg/ml for groups I and II and 2 mg/ml for group III as
summarized in Table 1.
The Modified Vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) vaccine
was manufactured by WRAIR Pilot Bio production facility (Forest Glen, MD, USA). The
HIV-MVA vaccine is a recombinant live non-replicating poxvirus vector that was genetically
Fig 1. Number of individuals screened, randomized and allocated to the three vaccination groups and
withdrawn from the trial.
doi:10.1371/journal.pone.0119629.g001
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engineered to express HIV-1 gp150 (Subtype E, isolate CM235) and Gag and Pol (integrase-de-
leted and reverse transcriptase nonfunctional, Subtype A, isolate CM240), both under control
of the early and late mH5 promoter. A description of the MVA-CMDR vaccine is given by Earl
et al [25]. Pre-study titration indicated a concentration of up to 108 pfu/ml.
Safety Assessments
Safety assessments were performed at each visit after the first immunization using an open
question, and by soliciting information on adverse events recognized to be associated with li-
censed vaccines. These were local (pain, redness, swelling and induration) and general
(fever, headache, malaise, chills, nausea, vomiting, myalgia and arthralgia). Participants were
also asked to make a daily record of these events in a diary card for seven days after each im-
munization. The diary card was reviewed by the study team and transcribed into the case re-
port form. The study team monitored vital signs before and immediately after each
immunization. Routine laboratory parameters (complete blood count, ALT, direct and indi-
rect bilirubin, random blood glucose and creatinine) were collected at 2 weeks after each
immunization.
Participants were given instructions on how to fill in the diary card and how to measure
temperature, local swelling and grading of the symptoms based on predefined criteria. The
study participants were also required to record or report on any medications used during the
entire study duration. The clinical and laboratory events were graded for severity as either
mild, moderate, severe based on the DAIDS toxicity scale (Division of AIDS, Natl. Institutes of
Health) [26] except for neutropenia that was considered as mild with levels of 1100 cells/μl that
is lower than the DAIDS scale and was based on the local reference ranges. HIV infection was
regarded as a grade 4 event according to the study protocol. The clinical events were defined as
solicited or non-solicited events. Each of the clinical events that occurred was evaluated for a
relationship to vaccination and was classified as not related, probably not related, possibly re-
lated, probably related and definitely related to the study products.
Urinalysis, pregnancy and HIV tests were performed at screening, on the day of each vacci-
nation and during the final visit. All women were required to have a negative pregnancy test at
screening and prior to each vaccination.
Participants who were HIV infected or pregnant were stopped from further vaccination but
were followed up until the end of the trial or post-delivery for pregnant women. Monitoring
for HIV-1 infection was performed using a sequential algorithm of Murex HIV antigen/anti-
body combination (Diasorin S.p.A, Dartford, UK) and Enzygnost
1
HIV Integral II (Siemens
Health Care, Marburg, Germany) enzyme-linked immunosorbent assays followed by INNO-
LIA™HIV I/II immunoblot (Innogenetics, Gent, Belgium) line immunoassay and Amplicor
1
HIV-1 DNA test version 1.5 (Roche Molecular Systems, Inc., Branchburg, NJ, USA) in case of
reactive ELISA results for MUHAS center. For NIMR-MMRC center, HIV testing was per-
formed using Biorad GS HIV-1/HIV-2 PLUS O EIA. If the EIA indicated HIV infection twice,
Biorad GS HIV-1 Western Blot, Biorad laboratories GmbH, Munich, Germany was performed,
followed by COBAS TaqMan HIV-1 test, v.2.0 Roche. Only cases with detectable HIV-RNA
were considered HIV infected, reports to the study clinics were termed HIV infected or not in-
fected to maintain blinding.
A twelve lead electrocardiography (ECG) and troponin tests were performed at screening
and 2 weeks after each HIV-MVA vaccination to monitor for possible peri/myocarditis accord-
ing to US FDA requirements. A panel of two independent experienced cardiologists interpreted
the ECGs.
TaMoVac01: HIV-1 DNA Prime/MVA Boost Vaccine Trial
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Immunological Assessments
Whole blood samples for analysis of cell-mediated immune responses were collected in vacu-
tainer tubes containing sodium heparin as anticoagulant. Peripheral blood mononuclear cells
(PBMC) were purified using LeucoSep tubes according to the manufacturer´s instructions
(Greiner Bio-One).
IFN-γ ELISpot assays were performed using the human IFN-γ ELISpotPLUS kit in a two-
step detection system according to the manufacturer’s instructions (Mabtech, Nacka, Sweden)
as previously described [20]. Freshly prepared purified PBMCs were used in the assay. Phyto-
haemagglutinin (PHA, positive control), a peptide pool (CEF) composed of a panel of 23 pep-
tides from cytomegalovirus (CMV), Epstein-Barr virus and influenza virus [27], a peptide pool
of 138 peptides (15 mers with an overlap of 11 amino acids) spanning the pp65 protein of
human CMV (PepMix, JPT, Berlin, Germany) and HIV-1 specific peptide pools representing
MVA-CMDR subtype A Gag and subtype E envelope (Env) were used for stimulation (purity
>80%, JPT, Berlin, Germany). A final concentration of 5 μg/ml was used for PHA and CEF.
The pp65 CMV peptide pool and the two MVA-CMDR-specific peptide pools were used at
1 μg/ml. RPMI medium without stimuli was used as negative control (background). Fifty mi-
croliters cell suspension of PBMC was added to each well giving 2x105 cells/well. The plates
were incubated for 20 hours at 37°C, with 7.5% CO2.
Frequencies of antigen-specific spot-forming cells (SFC) were measured using an automated
Immunospot analyzer (CTL-Europe, Bonn, Germany). Results were expressed as SFC per mil-
lion PBMCs and were calculated for each pool of peptides as follows: 5 x the mean SFC from
three stimulated wells, without subtracting background. ELISpot responses were considered
positive if the number of SFC was>55 spots/106 PBMC and at least 4 times the background
value. Data where background responses in three medium wells exceeded a median of 60 per
million PBMCs were excluded from analyses.
For the determination of CD4+ and CD8+ T cell responses, a 4-colour ICS assay was per-
formed on fresh PBMC which had been rested overnight following the purification procedure
as detailed previously [20]. 4-color ICS testing was performed on samples from only one center
(MUHAS). Briefly, PBMC were incubated with co-stimulatory anti-CD28 (1 μg/ml) and anti-
CD49d (1 μg/ml) monoclonal antibodies (Becton Dickinson, BD Pharmingen, San Diego, CA),
in either medium only (negative control) or in medium containing stimuli and brefeldin A
(0.5 μg/ml) (Sigma, St. Louis, MO). Staphylococcal enterotoxin A and B (SEAB, 1 μg/ml) (posi-
tive control) (Sigma, St. Louis, MO), a CEF peptide pool (1μg/ml), a CMV peptide pool (Pep-
Mix, 0.5μg/mL), two HIV-1 Gag-specific peptide pools representing the HIV-DNA vaccine or
MVA-CMDR vaccine and a HIV-1 Env-specific peptide pool representing MVA-CMDR were
used for stimulation. The cells were incubated for 6 hours at 37°C in a 7.5% CO2 incubator and
the stimulated cells were stored at 4°C overnight prior to staining with an antibody cocktail con-
taining anti-CD3–APC, anti-CD4–FITC, anti-CD8–PerCpCy5.5, anti-IFN-γ-PE and anti-IL-
2-PE (Becton Dickinson, San Jose, CA). Acquisition of samples was performed using a FACSCa-
libur flow cytometer and samples were analyzed using FlowJo software, version 8.7.1 (Tree Star,
Ashland, OR). A minimum of 50,000 CD3+ lymphocytes per well was required for a sample to
be included in the analysis. Background reactivity to Gag and Env peptide pool stimulation was
defined using pre-immunization samples collected from the vaccinees. ICS responses were con-
sidered positive if they were at least 2.5-fold higher than the mean of background (medium sam-
ples) and above 0.05% for CD4+ T lymphocytes and above 0.1% for CD8+ T lymphocytes.
Binding antibodies to native gp160 (IIIB, Advanced Biotechnologies Inc.) were tested using
a standardized enzyme-linked immunosorbent assay (ELISA). Starting from a dilution of
1:100, two-fold dilution steps were employed to determine antibody titres [22].
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All safety and immunological laboratory tests were performed at the Department of Micro-
biology and Immunology at the MUHAS and at the MMRCmain laboratories at the respective
centers. These two laboratories implement strict internal quality control programs and partici-
pate in external proficiency testing programs including College of American Pathologists
(CAP), United Kingdom National External Quality Assurance Scheme (UKNEQAS) and USA
Virology Quality Assurance (VQA).
Study Endpoints
Primary safety endpoints. The primary safety endpoint was defined as any grade 3 and
above clinical or laboratory adverse event that occurred after the first immunization up until
24 weeks from the last immunization.
Secondary safety endpoints. The secondary safety endpoint was defined as any grade 1 or
2 clinical or laboratory adverse event that occurred after the first immunization up until 24 weeks
from the last immunization.
Primary immunogenicity endpoint. The primary immunogenicity end point was as-
sessed as positive Interferon-γ ELISpot responses to either Gag and/or Env peptide pools 2
weeks after the second HIV-MVA vaccination in participants that completed the immuniza-
tion regimen.
Secondary immunogenicity endpoints. Secondary immunogenicity endpoints were eval-
uated as the magnitudes of the IFN-γ ELISpot responses to Gag or Env peptide pool stimula-
tion determined two weeks after the first and second HIV-MVA vaccination, the proportion of
4-colour ICS IFN-γ/IL-2 responders and the magnitude of IFN-γ/IL-2 responses to Gag and
Env peptide pool stimulations two weeks after the first and second HIV-MVA vaccination, as
well as the antibody responses to HIV-1 subtype B gp160 as determined by ELISA in samples
collected four weeks after the second HIV-MVA vaccination.
Statistical Methods
Assuming a response rate of 100% in the group that received the ‘standard regimen’ of 5 injec-
tions with a total dose of 1000 μg HIV-DNA x 3 followed by HIV-MVA boosts, we required 36
participants in each group to be able to detect a 20% difference in the groups that received the
simplified HIV-DNA regimen with a power of 80% and 5% significance level.
Clinical and laboratory safety data were recorded in study specific case report forms and en-
tered twice into the study database which was programmed in SQL. Discrepancies between the
data records were resolved before the data files were extracted for analysis. Immunological data
were exported directly into Excel from the ELISpot reader and thereafter into STATA version
11 for analysis.
Datasets were created for analysis as follows: The safety analysis dataset included all solic-
ited, non-solicited and routine laboratory data that were collected after the first vaccination up
to 24 weeks after the 2nd HIV-MVA/Placebo vaccination. The solicited and non-solicited
events were summarized according to the maximum grade of severity as mild, moderate or se-
vere. Comparisons of the proportion of participants with solicited and non-solicited events
were made between the randomization groups in relation to the HIV-DNA and HIV-MVA
vaccinations. Routine laboratory data were summarized as the number of events by grades and
proportion of participants with events by grades in relation to the randomization group.
The immunological analysis dataset was limited to participants who completed all the
scheduled immunizations and included all responses to interferon-γproduction by ELISpot
assay to Gag-CMDR and/or Env-CMDR peptides, measured as the proportion of participants
TaMoVac01: HIV-1 DNA Prime/MVA Boost Vaccine Trial
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with a valid assay that had ELISpot responses and the median magnitude of these responses by
peptide pool.
We compared the proportion of responders in the 2 injection-separated-plasmid group to
the standard 5 injection-separated-plasmid group. We thereafter compared the proportion of
responders in the 2 injection—combined-plasmid group to the 2 injection-separated-plasmid
group. Finally we compared the proportion of responders in the 2 injection-combined-
plasmid-group to the standard 5 injection-separated-plasmid group.
Comparisons between proportions were made using chi-square test or Fisher’s exact test
where appropriate, and no adjustments were made for multiple comparisons. A two sided p-
value of<0.05 was considered to be statistically significant.
The magnitudes of ELISpot responses were measured two weeks after the first HIV-MVA
and two weeks after the second HIV-MVA. The magnitude of responses in responding individ-
uals only was described using median and interquartile range (IQR), and comparisons between
the randomization groups were made by Wilcoxon rank-sum test.
The data were analyzed using STATA version 11 (StataCorp LP 1985–2011, College, Sta-
tion, TX, USA).
Results
Demographics, Recruitment and Inclusion
Overall, 743 volunteers attended the briefing and pre-screening sessions, of whom 508 (68%)
proceeded to a screening visit between March 2010 and June 2011. Of those screened, 129
(25%) were enrolled and these individuals were balanced across the randomization groups for
age, sex and center (Table 2). Scars compatible with previous vaccinia vaccination were ob-
served in 7% (9/129) of the enrollees whose age range was 29–38 years.
The overall briefing to screening to enrollment ratio was 6:4:1. Three hundred and seventy
nine participants were screened out, and more than one reason could be given. Frequent rea-
sons for screen out included laboratory abnormalities, 102 (27%), medical reasons, 76 (20%),
inability to comply with the study schedule, 61 (16%), not returning for enrolment, 41 (11%),
failed test of understanding, 39 (10%), and high risk behaviour related to HIV acquisition, 25
(7%). Of note, ECG abnormalities in otherwise healthy volunteers contributed to the screen
out in 32 participants (8%). The HIV prevalence among those screened was 1% (3/235) for Dar
es Salaam and 6% (16/273) for Mbeya.
Withdrawals/Termination from Vaccination
The retention and adherence to the study schedule by the participants is shown in Fig 1. Nine-
teen participants did not complete the study schedule (not shown in Fig 1). Of these, 15 partici-
pants did not complete the vaccination schedule. As a result nine participants were replaced in
the randomization scheme during recruitment. The reasons for early vaccination terminations
included: not meeting the eligibility criteria due to an abnormal ECG (1), pregnancy (3), lost to
follow up (5), consent withdrawn (2), HIV infection (2). Vaccinations were discontinued in (2)
participants following adverse events. One had moderate itching and excoriation at the injec-
tion site that occurred after the 2nd HIV-DNA vaccination and the other had non-specific ST
changes on ECG after the 1st HIV-MVA vaccination. He had no clinical symptoms, the tropo-
nin test was negative and echocardiography did not suggest peri/myocarditis. Four other par-
ticipants relocated and could not continue visits after completing the vaccination schedule.
The last study visit was completed on the 13th of June 2012.
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Safety and Tolerability
Solicited adverse events. Of the 129 participants who received at least 1 immunization,
114 (88%) reported a local solicited event and 87 (67%) a solicited systemic adverse event that
started within one week of an immunization. The majority of these events were mild, and the
distribution by randomization groups and immunogens was similar as summarized in Fig 2a
and 2b for local and systemic adverse events respectively. The most common solicited local
event was pain, which occurred in 89 (69%) participants, three of whom experienced short du-
ration severe pain (1 post HIV-DNA, 2 post HIV-MVA). The most common systemic solicited
event was headache that occurred in 70 (54%) participants. In one participant (given 2 injec-
tions of combined HIV-DNA pools) moderate itching and excoriations after two HIV-DNA
vaccinations was observed and the participant was withdrawn from further vaccination.
Non-solicited adverse events. One hundred and seven participants reported 364 non-
solicited clinical adverse events, of which 270 (74%) were mild and 86 (24%) were moderate.
Table 2. Baseline characteristics.
Characteristics Group I. Group II Group III Placebo Total
2 injections, 600 μg
HIV-DNA combined pools
2 injections, 600 μg
HIV-DNA separated pools
5 injections, 1000 μg
HIV-DNA separated pools
n = 39 n = 38 n = 39 n = 13 n = 129
Site
MMRP 20 (51) 20 (53) 20 (51) 7 (54) 67 (52)
MUHAS 19 (49) 18 (47) 19 (49) 6 (46) 62 (48)
Sex
Female 16 (41) 16 (42) 15 (38) 7 (54) 54 (42)
Male 23 (59) 22 (58) 24 (62) 6 (46) 75 (58)
Age (years) 23 (20–29) 23 (20–27) 26 (20–31) 22 (19–24) 23 (20–29)
BMI (kg/m2) 22 (20–25) 22 (20–24) 23 (20–26) 25 (20–26) 22 (20–26)
Laboratory
Hemoglobin (g/dl) 15 (13–16) 15 (12–15) 15 (14–16) 14 (12–16) 15 (13–16)
White cell count
(109 cells/l)
4.8 (3.8–5.5) 4.7 (3.9–5.3) 4.9 (4.3–5.8) 5.2 (3.9–6.1) 4.8 (4.0–5.6)
Neutrophils (109
cells/l)
2.0 (1.5–2.8) 2.3 (2.0–2.7) 2.4 (1.8–3.0) 2.4 (2.1–2.6) 2.2 (1.8–2.8)
Lymphocytes (109
cells/l)
2.0 (1.6–2.3) 1.7 (1.4–2.2) 2.0 (1.5–2.4) 2.1 (1.8–2.6) 1.9 (1.5–2.3)
Platelets (109 cells/
l)
240 (197–275) 258 (199–305) 277 (227–315) 271 (215–322) 258 (211–311)
CD4+ cell count
(106 cells/l)
793 (660–955) 694 (589–856) 779 (652–958) 857 (686–971) 784 (630–924)
ALT (U/L) 18 (14–23) 18 (14–25) 16 (13–24) 15 (11–19) 17 (13–23)
Total Bilirubin
(μmol/l)
8 (5–11) 6 (4–11) 8 (6–10) 7 (4–10) 8 (5–11)
Direct Bilirubin
(μmol/l)
2 (2–3) 2 (1–3) 2 (2–3) 2 (2–3) 2 (2–3)
Creatinine (μmol/l) 59 (53–69) 58 (50–66) 60 (49–66) 51 (43–71) 59 (51–67)
Glucose (mmol/l) 4.3 (4.1–5.1) 4.5 (4.2–4.9) 4.5 (4.1–5.0) 4.4 (4.2–5.0) 4.4 (4.1–4.9)
Follow up (weeks) 65 (61–68) 66 (61–69) 66 (62–69) 66 (61–70) 66 (61–69)
Note: Values are numbers (%) or medians (interquartile ranges).
Combined refers to a combination of plasmid pools 1 and 2, separated refers to each plasmid pool given separately.
doi:10.1371/journal.pone.0119629.t002
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Eight (2%) were considered severe and three of these met the protocol criteria for a serious ad-
verse event (SAE). Two were HIV infections (both given the standard regimen of 5 injections
with separated HIV-DNA pools), detected at the time of the 2nd HIV-MVA boost. Based on
retrospective HIV-DNA analysis (Gen-Probe Aptima HIV-1) the infection time point for both
participants was possibly around the 1st HIV-MVA boost. The third SAE was a skull fracture
complicated by osteomyelitis (600 μg HIV-DNA combined group). Five other severe events
that did not meet the criteria for SAE included: a left axilla abscess (placebo group), a dislocated
knee associated with fainting (standard dose separate), and two participants with anemia (low
dose separate and placebo group). None of these events were considered to be related to
the vaccines.
Of the 364 non-solicited clinical events, 101 started within 2 weeks of an immunization, 75
occurred within 2 weeks of the HIV-DNA/placebo vaccinations, and 26 occurred within 2
weeks of the HIV-MVA/placebo vaccinations. The distribution by randomization groups was
similar as summarized in Table 3.
The majority of the adverse events, 194 (53.3%), were ‘not related’ to the vaccines, 165
(45.3%) were considered ‘probably not related’ to the vaccines, 5 (1.4%) were considered ‘possi-
bly related’ to the vaccines and 1 (0.3%) was considered as ‘probably related’ to the vaccines.
The five adverse events that were considered possibly related to vaccinations were: altered
menstruation cycles (2), herpes zoster (1), herpes labialis (1) and allergic conjunctivitis (1).
Of the non-solicited adverse events, infections were the most commonly reported. There
were 174 (48%) infections with the most common infections being: malaria, 51(14%), gastroen-
teritis, 16 (4%), upper respiratory tract infections, 15 (4%) and tonsillitis, 15(4%). Other non-
infectious non-solicited events that were frequently reported were headache, which was re-
ported in 25 participants (7%) and anemia requiring iron supplementation in 22 participants
(6%).
Laboratory adverse events. There were 287 laboratory adverse events detected according
to the DAIDS grading that occurred in 126 participants. Sixty-one (21%) events were detected
at safety visits within 2 weeks of an immunization in 41 (33%) participants. Of the 287 labora-
tory events 198 (69%) were mild, 67 (23%) were moderate, 15 (5%) were severe and 7 (2%)
Fig 2. Proportion and number of participants with (A) local and (B) systemic solicited adverse events post HIV-DNA and HIV-MVA by
randomization arm.
doi:10.1371/journal.pone.0119629.g002
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were of grade 4 severity. There was no difference in the proportion of participants with labora-
tory events between the randomization groups including placebo (data not shown).
Of the 22 grade 3 and above events that occurred in 12 participants, 1 event (neutropenia)
occurred within 2 weeks of vaccination. The majority, 15 (68%), of the severe laboratory events
were related to asymptomatic neutropenia, which occurred 12 to 24 weeks after the last vacci-
nation and were evenly distributed across the randomization groups.
One male participant (given 2 injections of combined HIV-DNA pools) presented with se-
vere elevation of ALT levels 1 month after the 2nd HIV-MVA. This was associated with tran-
sient excessive alcohol intake that resolved after counseling and abstinence with subsequent
normalization of the ALT levels.
Immunogenicity
IFN-γ ELISpot responses in the three study groups. The IFN-γ ELISpot response rates to
Gag and/or Env peptides two weeks after the second HIV-MVA boost were very high and did
not differ significantly between the groups primed with 2 injections of combined HIV-DNA
plasmid pools, 2 injections of separated plasmid pools, and 5 injections of separated plasmid
pools (response rates 90%, 97% and 97% respectively, Table 4). There was no significant differ-
ence in response rates to Env after the second HIV-MVA boost. However, after the first
HIV-MVA boost, there was a higher proportion of Env responders in the group given 2 injec-
tions of separated plasmid pools compared to the group given 5 injections of separated plasmid
pools (p = 0.037).
The overall magnitude of IFN-γ ELISpot responses in responders to Gag was significantly
higher after the first than after the second HIV-MVA (median 290 vs 200 SFC/million PBMCs,
p<0.001, calculated from but not shown in Table 5) while the magnitude of Env responses
after the first and second HIV-MVA was not significantly different (medians 205 vs 155 SFC/
million PBMCs, p = 0.15). The magnitude of IFN-γ ELISpot responses to Gag and Env are
shown in Fig 3 and Table 5. The magnitude of IFN-γ ELISpot responses to Gag or Env was not
significantly different between the three study groups after the second HIV-MVA. However
the median of SFC/million PBMCs to Env was higher after the first HIV-MVA boost in the
Table 4. Proportion of ELISpot responders to Gag and/or Env peptides two weeks post first and second HIV-MVA vaccination in each of the
HIV-DNA primed groups.
Randomization group
Peptide Pool Group I Group II Group III P-value (95% CI) P-value (95% CI) P-value (95% CI)
2 injections, 600 μg
HIV-DNA combined
2 injections, 600 μg
HIV-DNA separated
5 injections, 1000 μg
HIV-DNA separated
Group (I vs III) Group (II vs III) Group (I vs II)
n (%) n (%) n (%)
2 weeks after 1st HIV-MVA
Gag-CMDR 24/28 (86) 26/30 (87) 27/31 (87) 1.00 (-18.9, 16.1) 1.00 (-17.4, 16.5) 1.00 (-18.7, 16.8)
Env-CMDR 18/27 (67) 24/29 (83) 18/31 (58) 0.50 (-16.3, 33.5) 0.037 (2.5, 46.8) 0.17 (-38.6, 6.4)
Gag and/or
Env-CMDR
25/28 (89) 29/30 (97) 28/31 (90) 1.00 (-16.5, 14.4) 0.61 (-5.9, 18.6) 0.34 (-20.5, 5.8)
2 weeks after 2nd HIV-MVA
Gag-CMDR 22/29 (75) 29/32 (91) 25/30 (83) 0.48 (-28.0, 13.0) 0.47 (-9.4, 24.0) 0.12 (-33.3, 3.8)
Env-CMDR 23/28 (82) 21/30 (70) 25/30 (83) 1.00 (-20.7, 18.3) 0.22 (-34.5,7.8) 0.28 (-9.5, 33.8)
Gag and/or
Env-CMDR
26/29 (90) 31/32 (97) 29/30 (97) 0.35 (-19.8, 5.8) 1.0 (-8.6,9.0) 0.34 (-19.8, 5.4)
doi:10.1371/journal.pone.0119629.t004
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Randomization group P value
Group I Group II Group III Group II vs group III*; Group I vs group
II**; Group I vs group III***
2 injections 600 μg
HIV-DNA combined
Median (IQR)
2 injections 600 μg
HIV-DNA separated
Median (IQR)
5 injections1000 μg HIV-DNA
separated Median (IQR)
1st HIV-MVA Gag-CMDR 300 (190–640) 250 (135–565) 270 (130–660) *p = 0.90; **p = 0.50; ***p = 0.66
Env-CMDR 270 (145–310) 143(105–215) 180 (140–335) *p = 0.12; **p = 0.017; ***p = 0.60
2nd HIV-MVA Gag-CMDR 213 (140–375) 130 (100–285) 235 (140–320) *p = 0.18; **p = 0.37; ***p = 0.87
Env-CMDR 165 (110–295) 135 (85–200) 115 (80–160) *p = 0.72; **p = 0.24; ***p = 0.15
doi:10.1371/journal.pone.0119629.t005
Fig 3. Magnitude of IFN-γ ELISpot responses. The magnitude of IFN-γ ELISpot responses to (A) Gag and (B) Env two weeks after the first HIV-MVA
vaccination and to (C) Gag and (D) Env two weeks after the second HIV-MVA vaccination. Data is shown for each of the HIV-DNA primed groups. ELISpot
responses were considered positive if the number of SFC was >55 spots/million PBMCs and 4 times the background value. The dashed line is at a cut-off of
55 SFC/million PBMCs. Responders are shown by filled circles and non-responders are shown by open circles.
doi:10.1371/journal.pone.0119629.g003
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group given the 2 injections of combined plasmid pools compared to that found in vaccinees
receiving 2 injections of separated plasmid pools (p = 0.017).
Two out of 13 placebo recipients were positive in the IFN-γ ELISpot assay (not included in
the analysis). One placebo recipient was positive on one occasion out of a total of seven time
points. Another placebo recipient was sporadically positive and exhibited reactivity to either
Gag or Env peptides on four of seven occasions.
CD4+ and CD8+ T cell responses in the three study groups. The overall proportion of
vaccinees with CD4+ T cell responses to Gag and/or Env measured as IFN-γ/IL-2 producing
cells by ICS was not significantly different two weeks after the first as compared to two weeks
after the second HIV-MVA boost, 51% (23 of 45) and 47% (21 of 45), respectively (p = 0.67,
calculated from but not seen in Table 6). However, the overall CD8+ T cell response rate to Gag
and/or Env was significantly higher after the second HIV-MVA boost, 39% (17 of 44), com-
pared to 18% (8 of 44) after the first MVA boost (p = 0.029). The proportion of vaccinees with
CD4+ and CD8+ T cell responses to Gag and/or Env in the three study groups is shown in
Table 6. The CD4+ T cell response rates to Gag and/or Env peptides were not significantly
Table 6. The proportion of ICS responders to Gag or Env peptide pools two weeks after the first and second HIV-MVA vaccination in each of the
HIV-DNA primed groups.
CD4+ Responses CD8+ Responses






































n (%) n (%) n (%) n (%) n (%) n (%)
1st
HIV-MVA
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0.15*** 0.23***
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different between the two groups given the simplified 2 injection-HIV-DNA regimens or be-
tween any of the two groups and the group given the standard 5 injection-HIV-DNA regimen.
Neither was there a difference in CD8+ T cell response rates to Env. However, there was a trend
towards a higher CD8+ T cell response rate to Gag in the group receiving 5 injections of sepa-
rated HIV-DNA plasmids compared to the group given 2 injections of separated HIV-DNA
plasmids after the second HIV-MVA boost (p = 0.05, Table 6). The magnitudes of CD4+ and
CD8+ T cell responses to Gag and Env in the three groups are shown in Fig 4. Placebo recipi-
ents did not show any reactivity in the 4-color ICS assay.
Antibody response in the three study groups. Antibodies to native HIV-1 gp160 were
observed in 81 of 90 (90%) of the evaluable vaccinees 4 weeks after the 2nd HIV-MVA boost.
The response rate was similar in the three groups; 89% (24 of 27), 97% (29 of 30) and 85% (28
of 33), respectively (Fig 5). The median antibody titer was 400 in all three groups.
Discussion
This phase IIa HIV-1 vaccine immunogenicity trial builds on the previous HIVIS 03 phase I/II
trial that used the same multigene, multiclade HIV-DNA prime and HIV-MVA boost antigens
which demonstrated that HIV-DNA at a priming dose of 1000 μg given intradermally elicited
a higher and broader cellular immune response compared to a priming dose of 3800 μg of
HIV-DNA given intramuscularly [20]. The 1000 μg of HIV-DNA was administered in five dif-
ferent injections due to the limited volume that could be administered intradermally using the
Bioject needle-free device.
Fig 4. Magnitude of HIV-specific IFN-γ/IL-2 T cell responses. The magnitude of HIV-specific IFN-γ/IL-2 T cell responses in responders as assessed by
4-colour ICS two weeks after the first (upper panel) and second (lower panel) HIV-MVA vaccination presented as Gag reactivity of CD4+ T cells (panels A and
E) and of CD8+ T cells (panels B and F), and Env reactivity of CD4+ T cells (panels C and G) and of CD8+ T cells (panels D and H). The Gag-reactivity
represents reactivity to either the MVA-CMDR-specific peptide pools or the HIV-DNA-specific peptide pool. A Gag HIV-DNA-specific peptide pool response
is only given when the Gag MVA-CMDR-specific peptide pool response is negative. Gag-HIV-DNA-specific responses are given by triangles, while Gag and
Env-HIV-CMDR-specific responses are given by circles.
doi:10.1371/journal.pone.0119629.g004
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In the current trial we have shown that the regimen can be simplified by reducing the num-
ber of injections and by combining the HIV-DNA plasmids before boosting with the vaccinia-
based immunogen, HIV-MVA. We considered the five intradermal HIV-DNA injections with
a total of 1000 μg DNA to be the “standard” regimen, and compared this to two intradermal
HIV-DNA injections using a higher HIV-DNA concentration of 3mg/ml, leading to 600 μg in
total, termed the “simplified” regimen.
We also assessed the effect on the immune response of combining the HIV-DNA plasmids
into a single injection compared to separating the Gag and Env plasmid pools in two different
injections, since immunocompetition between Gag and Env antigens has been previously ob-
served in mouse experiments [24].
In accordance with what has been reported previously, there were no major safety concerns
with the use of HIV-DNA and recombinant HIV-MVA candidate vaccines and the events that
occurred were mild and tolerable, irrespective of the number of injections [20,21].
Two participants were discontinued from further immunizations due to adverse events.
One of them had ECG changes following the first HIV-MVA, but these were shown to be of no
clinical significance following further investigations. The other had moderate itching following
the first and second HIV-DNA vaccinations. However these events were not considered suffi-
ciently severe to interrupt a licensed vaccine regimen. In one participant an elevated ALT was
noted one month after the second HIV-MVA that was attributed to acute alcohol
induced hepatitis.
We observed a number of male study participants with transiently low neutrophil counts,
which commonly occurred 12–24 weeks from the last immunization. These participants had
significantly low neutrophil counts without clinical signs of infection or an increased suscepti-
bility to infection. This perhaps is an indication of low transient neutrophil count which could
be a normal variation in an African population, as has been described previously and regarded
as benign ethnic neutropenia [28,29,30].
Fig 5. Antibody endpoint titers. Antibody endpoint titers to native HIV-1IIIB subtype B gp160 one month
after the second HIV-MVA vaccination. Data is shown for each of the HIV-DNA priming groups. The dashed
line shows a titer of 100, corresponding to a 1:100 serum dilution, the lowest dilution used in the assay.
doi:10.1371/journal.pone.0119629.g005
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The simplified regimen with 2 intradermal injections of a total of 600 μg of HIV-DNA by
Bioject had a similar priming effect as the standard regimen of 5 intradermal injections of a
total of 1000 μg HIV-DNA, also given by the Bioject device. Further combining the plasmids
into one injection had a similar effect on the frequency of immune responses when compared
to separating the plasmids in two injections. With these findings the rather cumbersome regi-
men of 5 intradermal HIV-DNA injections at a somewhat higher dose of 1000 μg of HIV-DNA
given as separated plasmids could be simplified to a regimen of intradermal HIV-DNA prim-
ing injections at two sites with combined or separated plasmids. Administration of fewer injec-
tions has clinical and public health relevance since the acceptability of a lower total DNA dose
will reduce the cost of vaccine production. Presently these considerations are of importance es-
pecially when planning for larger future phase IIB or III clinical trials.
This study confirms the high response rates we observed in a previous study with this heter-
ologous regimen [20]. This could possibly be explained by the recent finding of potentiation of
immune responses by a boost with a heterologous vector and heterologous HIV-genes [31]
There is paucity of data in the literature on the effect of combining compared to separating
HIV-DNA antigens in humans. Studies in mice have indicated that separating the Gag from
Env plasmids resulted in an increased immune response to Env, while combining the peptides
made no difference in responses towards Gag [24]. We did not observe such effects in our
human study.
We observed that the HIV-specific CD4+ T cell response rates measured by ICS were com-
parable after the first and second HIV-MVA vaccinations. In contrast the HIV-specific CD8+
T cell response rates were significantly higher after the second HIV-MVA compared to the re-
sponse rates after the first HIV-MVA. Similarly, in a trial where GeoVax pGA2/JS7 HIV-DNA
was given as a prime and MVA/HIV62 as a boost, CD8+ T cells response rates increased after
the second dose of HIV-MVA in vaccinees who had received one or two HIV-DNA vaccina-
tions followed by the two HIV-MVA doses [32].
This study has some limitations. The highest concentration of HIV-DNA available was 3
mg/ml, thus a strict comparison of 2 and 5 injections could not be made since only 0.1 mL
could be delivered intradermally with the Biojector. However, this difference in total dose,
600 μg vs 1000 μg, did not significantly affect the simpler regimen. A new study is underway to
explore the effect of delivering 0.2mL intradermally with the Zetajet to address this problem.
The comparison of the HIV-specific ICS responses in the three study groups included a smaller
number of vaccinees than the corresponding comparison of IFN-γ ELISpot and antibody re-
sponses since 4-colour ICS was only performed at one of the two study sites. The choice of the
primary endpoint as IFN-γ ELISpot responses after the second HIV-MVA was not optimal
since we observed that the magnitude of ELISpot responses to Gag was higher after the first
HIV-MVA vaccination compared to the responses after the second HIV-MVA boost similar to
what was observed in our previous study [20]. Similar findings have also been reported in a
phase I trial that included priming with two doses of HIV-DNA subtype C and boosting with
two doses of recombinant HIV-MVA vaccines [33]. In the present trial, we employed a short 4
month interval between the two HIV-MVA vaccinations. A lack of enhanced ELISpot re-
sponses to Gag peptides was also observed in our previous study when a 12 month interval was
used between the two HIV-MVA vaccinations [20].
Our three immunization schedules also induced similar antibody titers to HIV Env. As was
observed in the HIVIS03 study [20], a majority of the vaccinees had binding antibodies to
gp160 following the second HIV-MVA boost. A study of antibody responses in a subset of the
vaccinees who received recombinant gp140 in GLA adjuvant after the second HIV-MVA
boost, will be presented in a separate paper
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In conclusion, intradermal HIV-DNA priming with a simplified regimen of 2 injections of
600 μg HIV-DNA, with combined plasmid pools followed by boosting with HIV-MVA is safe,
and elicits cellular and antibody immune responses that are similar to the standard regimen of
5 injections of 1000 μg HIV-DNA, with separated plasmid pools. It is thus possible to explore
if the immune response to HIV-DNA can be further enhanced with intradermal electropora-
tion of HIV-DNA given in 2 injections of combined plasmid pools at a total dose of 600 μg in
the ongoing phase II, TaMoVac-II study.
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